JIC
AKBA icon

Johnson Investment Counsel’s Akebia Therapeutics AKBA Stock Holding History

Johnson Investment Counsel’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-62,460
Closed -$180K – 671
2021
Q3 		$180K Hold
62,460
– – ﹤0.01% 630
2021
Q2 		$237K Hold
62,460
– – ﹤0.01% 577
2021
Q1 		$211K Hold
62,460
– – ﹤0.01% 579
2020
Q4 		$175K Hold
62,460
– – ﹤0.01% 576
2020
Q3 		$157K Buy
62,460
+500
+0.8% +$4.39K ﹤0.01% 556
2020
Q2 		$841K Buy
+61,960
New +$641K 0.02% 312
2020
Q1 		– Sell
-76,141
Closed -$481K – 532
2019
Q4 		$481K Hold
76,141
– – 0.01% 422
2019
Q3 		$298K Hold
76,141
– – 0.01% 501
2019
Q2 		$368K Hold
76,141
– – 0.01% 476
2019
Q1 		$623K Buy
76,141
+14,679
+24% +$101K 0.01% 377
2018
Q4 		$339K Hold
61,462
– – 0.01% 460
2018
Q3 		$542K Hold
61,462
– – 0.01% 423
2018
Q2 		$613K Sell
61,462
-105
-0.2% -$1.05K 0.02% 399
2018
Q1 		$586K Buy
61,567
+105
+0.2% +$1.47K 0.02% 388
2017
Q4 		$913K Sell
61,462
-1,000
-2% -$16.6K 0.02% 288
2017
Q3 		$1.23M Sell
62,462
-859
-1% -$13.2K 0.03% 222
2017
Q2 		$909K Sell
63,321
-2,071
-3% -$26.3K 0.03% 268
2017
Q1 		$601K Buy
65,392
+2,930
+5% +$28.6K 0.02% 339
2016
Q4 		$650K Sell
62,462
-37,303
-37% -$321K 0.02% 307
2016
Q3 		$902K Buy
99,765
+2,930
+3% +$24.9K 0.03% 236
2016
Q2 		$724K Buy
96,835
+2,930
+3% +$25.6K 0.02% 267
2016
Q1 		$846K Buy
93,905
+2,930
+3% +$23.8K 0.03% 239
2015
Q4 		$1.18M Sell
90,975
-7,026
-7% -$71.7K 0.04% 197
2015
Q3 		$946K Buy
98,001
+22,613
+30% +$207K 0.03% 220
2015
Q2 		$775K Buy
+75,388
New +$643K 0.03% 246

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Johnson Investment Counsel's AKBA Position: Q4 2021 in Review

Johnson Investment Counsel sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 62,460 shares — an estimated $180K sold.

Johnson Investment Counsel first reported a position in AKBA in Q2 2015 and held it in 25 quarters. The position peaked at $1.23M in Q3 2017. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

  • Johnson Investment Counsel reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Johnson Investment Counsel sold 62,460 Akebia Therapeutics shares in Q4 2021, an estimated $180K.
  • Johnson Investment Counsel first reported a position in Akebia Therapeutics in Q2 2015 and held it in 25 quarters.
  • Johnson Investment Counsel's Akebia Therapeutics position peaked at $1.23M in Q3 2017.
  • 133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on Johnson Investment Counsel's 13F filing for Q4 2021, filed 15 Feb 2022.